Advertisement Abbott Products pays $48m milestone to Depomed - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Abbott Products pays $48m milestone to Depomed

Abbott Products has given $48m milestone payment to Depomed following the US Food and Drug Administration's approval of Gralise (gabapentin) tablets.

Gralise tablet is developed by Depomed and is licensed to Abbott Products in US, Mexico and Canada.

The FDA has approved Gralise tablets as once daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of the rash associated with shingles.

Depomed is a specialty pharmaceutical company with one approved product on the market and has developed another approved product, Glumetza.